Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-Tnews2026-09-08T14:08:51+00:00September 8th, 2026|Endpoints News|
BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-Tnews2026-09-08T11:00:53+00:00September 8th, 2026|Endpoints News|
Diabetes cell therapy biotechs Sernova and Seraxis to mergenews2026-09-08T11:00:21+00:00September 8th, 2026|Endpoints News|
#ERS26: Beam says AATD base editing data hold up after one yearnews2026-09-08T08:30:35+00:00September 8th, 2026|Endpoints News|
China deaths reignite debate about using viruses to deliver CRISPR therapiesnews2026-09-02T14:00:43+00:00September 2nd, 2026|Endpoints News|
Typewriter raises $56M for jumping gene technology and in vivo CAR-T therapiesnews2026-09-02T11:00:57+00:00September 2nd, 2026|Endpoints News|
ARPA-H awards $125M for manufacturing custom RNA therapies on demandnews2026-09-01T18:32:08+00:00September 1st, 2026|Endpoints News|
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also pausednews2026-09-01T00:01:19+00:00September 1st, 2026|Endpoints News|
#ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapynews2026-08-28T14:30:23+00:00August 28th, 2026|Endpoints News|
An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapiesnews2026-08-26T14:24:29+00:00August 26th, 2026|Endpoints News|
